hVIVO plc Director's Dealings (0609Z)
08 Janvier 2020 - 8:01AM
UK Regulatory
TIDMHVO
RNS Number : 0609Z
hVIVO plc
08 January 2020
hVIVO plc
("hVIVO" or the "Company")
Director's Dealings
London, UK, 8 January 2020: hVIVO plc (AIM: HVO), an industry
leading clinical development services business pioneering human
disease models based upon viral and allergen challenge, announces
that, application has been made to AIM for the admission of 30,602
new ordinary shares of 5.0p each in the Company (the "New Ordinary
Shares").
The New Ordinary Shares have been allotted pursuant to the
purchase by Jim Winschel (Non-Executive Director) of new ordinary
shares, under the terms of his letter of appointment as set out in
the Company's announcement of 4 November 2014 which stated that Mr
Winschel had entered into a binding commitment to purchase GBP4,000
of hVIVO plc New Ordinary Shares per quarter.
The New Ordinary Shares represent Mr Winschel's investment for
the quarter ended December 2019. On 7 January 2020, Mr Winschel
invested in an additional 30,602 ordinary shares, at a price of
11.93 pence per share.
Following admission of the New Ordinary Shares to trading on
AIM, the total number of Ordinary Shares with voting rights in
issue will be 83,583,946 and this figure may be used by
shareholders as the denominator for the calculations by which they
will determine if they are required to notify their interest in, or
a change to their interest in, the Company under the Financial
Conduct Authority's Disclosure and Transparency Rules.
Admission of the New Ordinary Shares ("Admission"), which will
rank pari passu in all respects with the Company's existing shares
in issue, is expected to occur on 13 January 2020. Following
Admission, Mr Winschel will be interested in a total of 185,150
ordinary shares of 5.0p in the Company, representing 0.2% of the
Company's issued share capital.
The notification below, made in accordance with the requirements
of the EU Market Abuse Regulation, provides further detail:
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them
1 Details of the persons discharging managerial responsibilities/persons
closely associated
a) Name Jim Winschel
--------------------------- --------------------------------------------
2 Reason for the notification
-------------------------------------------------------------------------
a) Position/ Non-Executive Director
status
--------------------------- --------------------------------------------
b) Initial notification/ Initial Notification
Amendment
--------------------------- --------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-------------------------------------------------------------------------
a) Name hVIVO plc
--------------------------- --------------------------------------------
b) Legal Entity N/A
Identifier
--------------------------- --------------------------------------------
4 Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
-------------------------------------------------------------------------
a) Description Ordinary shares of 5 pence each
of the financial
instrument,
type of instrument GB00B6ZM0X53
Identification
code
--------------------------- --------------------------------------------
b) Nature of Acquisition of ordinary shares
the transaction
--------------------------- --------------------------------------------
c) Currency GBP
--------------------------- --------------------------------------------
d) Price(s) and Director Price (p) Volume
volume(s) Jim Winschel 11.93 30,602
---------- -------
---------------------------
e) Aggregated
information
- Aggregated
volume
- Price 30,602
- Aggregated 11.93
total
GBP3,650.80
--------------------------- --------------------------------------------
f) Date of the 7 January 2020
transaction
--------------------------- --------------------------------------------
g) Place of the London Stock Exchange, AIM
transaction
--------------------------- --------------------------------------------
For further information please contact:
Anesh Patel (Interim Finance Director & Company Secretary) +44 207 756 1300
Fleur Wood (EVP, Investor Relations & Communications)
Numis Securities Limited +44 207 260 1000
Freddie Barnfield / Huw Jeremy (Nominated Adviser)
James Black (Corporate Broking)
FTI Consulting
Simon Conway / Victoria Foster Mitchell +44 203 727 100
Notes to Editors:
hVIVO is an industry leading clinical development services
business supporting product development for customers developing
antivirals, vaccines and respiratory therapeutics. Leveraging human
disease models in human rhinovirus (HRV), RSV, Influenza (Flu)
Asthma and chronic obstructive pulmonary disease (COPD), the hVIVO
platform illuminates the entire disease cycle in people from
healthy to sick and back to health. Based in the UK, market leader
hVIVO has conducted 56 clinical studies and inoculated over 2900
volunteers.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
DSHUPUAUGUPUGRM
(END) Dow Jones Newswires
January 08, 2020 02:01 ET (07:01 GMT)
Hvivo (LSE:HVO)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Hvivo (LSE:HVO)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024
